/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos · Oct 23, 2026

Niagara positive but two similar chemo-IO MIBC trials negative; pathCR delta didn't predict survival. EV+Pembro likely future standard.

EV plus pembrolizumab likely supersedes Niagara despite access gaps

Tom says perioperative EV-pembrolizumab produced hazard ratios of 0.53 and 0.60 versus Niagara's 0.68 and 0.75, with path CR jumping to 55%. Rob still expects Niagara to remain relevant until EV is licensed and reimbursed in many countries. Access barriers, not just efficacy, shape near-term standard of care.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Niagara's win may reflect higher-risk patients, not better drug

Niagara's control arm had 60% two-year event-free survival versus about 70% in the negative trials. The discussion says this makes Niagara the highest-risk population, where more events and greater risk can let an immune-therapy benefit show up. That may explain more than drug differences alone.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Baseline ctDNA imbalance may have sunk nivolumab trial

Rob notes the nivolumab trial presented circulating tumor DNA data and more patients in the nivolumab arm had detectable ctDNA at baseline, a strong poor prognostic factor. He says this is not a full explanation but illustrates unseen imbalances that can appear despite randomization. Such imbalances can swing large trials.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Gemcitabine-cisplatin may blunt immunotherapy's perioperative benefit

Tom argues platinum chemotherapy, including gemcitabine-cisplatin, is inhibitory to immunotherapy, and he thinks most benefit in these perioperative trials comes from the adjuvant period. He notes survival curves separate mainly after chemotherapy stops, when some patients finally receive immune therapy alone. That timing suggests antagonism, not synergy, during chemo.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Early immunotherapy beats waiting for adjuvant therapy after cystectomy

Tom says he sees no big role for adjuvant immune therapy because waiting for neoadjuvant chemotherapy and cystectomy means many patients never reach that phase. He prefers early immune therapy, as in Niagara, because some patients are cured with neoadjuvant treatment. This sequencing argument favors perioperative IO over postoperative-only IO.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Repeating three large trials would not reproduce same results

Tom says he is sure that rerunning Niagara, Energize, and the pembrolizumab trial would not produce the same two negatives and one positive. He argues randomized phase 3 trials are imperfect and vulnerable to noise, chance, and unseen imbalances. That should temper how confidently we interpret any single result.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago

Similar path CR gains did not predict survival outcomes

Rob points out all three chemo-IO trials raised pathological complete response by roughly 8-10%, yet only Niagara improved survival. He says path CR is not clinically meaningful by itself and has never been proven as a surrogate for event-free or overall survival. So similar activity signals cannot explain divergent outcomes.

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC thumbnail

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

The Uromigos·a month ago